Publications

orange__line

The ultimate goal of MedSIR projects is the publication of its study results, whether in peer-reviewed journals or at a number of national and international congresses and conferences in the form of abstracts, posters or oral presentations. Since its onset, MedSIR has consistently been present at the major Oncology meetings worldwide and will continue to do so as its activity increases and its initial projects soon come to an end while new ones come to light.

Over the last few years MedSIR has presented abstracts from PARSIFAL, THELMA, PIQHASSO, MERIBEL, EXCAAPE, SLLIP and other studies at the prestigious WCLC, ESMO, ASCO and SABCS international congresses.

Just click on each tab below for more information about any given publication.
  • PROJECT ABSTRACTS (Posters, presentations, etc.) CONGRESS YEAR
    SLLIP Spanish Lung Liquid vs. Invasive biopsy Program Evaluation
    Download this abstract
    ESMO 2018
    SLLIP Spanish Lung Liquid vs. Invasive biopsy Program Evaluation
    Download this abstract
    WCLC 2018
    KELLY A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes.
    Download this abstract
    AACR 2018
    PHENOMENAL Multicenter open-label, phase II trial, to evaluate the efficacy and safety of liposomal irinotecan (nal-IRI) for progressing brain metastases in patients with HER2-negative breast cancer.
    Download this abstract
    AACR 2018
    NOBROLA A two-stage Simon Design phase II study for NOn-BRCA metastatic BReast cancer (MBC)patients with homologous recombination deficiency treated with OLAparib single agent.
    Download this abstract
    AACR 2018
    PHERGain Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study.
    Download this abstract
    SABC 2017
    SLLIP Prospective comparison of liquid biopsy to standard of care tissue testing in metastatic, non-squamous, nsclc patients spanish lung liquid vs. invasive biopsy program.
    Download this abstract
    ESMO 2017
    EXCAAPE A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational status.
    Download this abstract
    ESMO 2017
    PIQHASSO Open label, non-randomized, multicenter phase I/IIA study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC).
    Download this abstract
    SABCS 2016
    THELMA Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC).
    Download this abstract
    SABCS 2016
    POLEN Preoperative OLaparib in early-stage ENdometrial cancer (EC): a window of opportunity trial to evaluate the parp inhibition effect, targeting cell cycle-related proteins.
    Download this abstract
    ESMO 2016
    MERIBEL Single-Agent Eribulin as First-Line Therapy for Taxane-Resistant HER2[-] Metastatic Breast Cancer (MBC) Patients (pts).
    Download this abstract
    ESMO 2016
    PARSIFAL A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC).
    Download this abstract
    ASCO 2016
    EROS Prognostic relevance of prior endocrine treatments in overall survival (OS) at the time of first line chemotherapy in ER[+]/HER2[-] advanced breast cancer (ABC) patients.
    Download this abstract
    SABCS 2015
    FB-7 PD5-04: NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer. SABCS 2015
    TRASTYVERE Final results from Trastyvere study: A retrospective analysis of heavily pretreated HER2-positive metastatic breast cancer (mbc) patients treated in Spain with lapatinib plus trastuzumab as compassive therapy.
    Download this abstract
    SABCS 2014
    MERIBEL Efficacy of eribulin in first Line of taxane resistant patients with her2-negative metastatic breast cancer.
    Download this abstract
    SABCS 2014
    TRASTYVERE Preliminary results from TRASTYVERE study: A retrospective analysis of HER2-positive (HER2) metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T)
    Download this abstract
    ECCO/ASCO 2014
    TRASTYVERE Trastuzumab & Lapatinib in HER2 positive mbc patients previously treated with trastuzumab and/or lapatinib.
    Download this abstract
    SEOM 2014
    MERIBEL MERIBEL study: efficacy of eribulin in first Line of taxane resistant patients with her2-negative metastatic breast cancer. SEOM 2014

    Other MedSIR related articles

  • ARTICLES AUTHORS JOURNAL YEAR
    Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
    Link to PubMed.org
    Cortes J,
    et al.
    Ann Oncol 2018
    Breast cancer in 2017: Spurring science, marking progress, and influencing history.
    Link to PubMed.org
    Perez-Garcia J,
    et al.
    Nat Rev Clin Oncol 2018
    Targeting FGFR pathway in breast cancer.
    Link to PubMed.org
    Perez-Garcia J,
    et al.
    Breast 2018
    Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice.
    Link to PubMed.org
    Melo Gagliato D,
    et al.
    Biochim Biophys 2017
    Biological Effects of Temsirolimus on the mTOR Pathway in Endometrial Carcinoma: A Pharmacodynamic Phase II Study.
    Link to PubMed.org
    Santacana M,
    et al.
    Int J Gynecol Cancer 2016
    Translating neoadjuvant therapy into survival benefits: one size does not fit all.
    Link to PubMed.org
    J. Cortés,
    et al.
    Nat Rev Clin Oncol 2016
    A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.
    Link to PubMed.org
    A. Llombart-Cussac,
    et al.
    Breast 2014
    New approach to cancer therapy based on a molecularly defined cancer classification.
    Link to PubMed.org
    J. Cortés,
    et al.
    CA Cancer J Clin 2014
    Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
    Link to PubMed.org
    L. De Mattos-Arruda,
    et al.
    Mol Oncol 2014
    Bone metastases: Causes, consequences and therapeutic opportunities.
    Link to PubMed.org
    J. Perez-García,
    et al.
    EJC Suppl 2013
    The effect of biology in the treatment of small breast tumors.
    Link to PubMed.org
    J. Perez-García,
    et al.
    Am Soc Clin Oncol Educ Book 2013

    Other MedSIR related articles